SequelSEC

USANA HEALTH SCIENCES INC USNA

Medicinal Chemicals & Botanical Products · CIK 0000896264 · Fiscal year ends 0103

AnnualQuarterlyTTM
Revenue
$223.27M
Fiscal year ended 2026-07-04
Operating income
-$20.00M
Fiscal year ended 2026-07-04
Free cash flow
$20.16M
Fiscal year ended 2026-07-04

USANA HEALTH SCIENCES INC (USNA) reported revenue of $223.27M and net income of -$21.38M for the fiscal year ended 2026-07-04. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from USANA HEALTH SCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Medicinal Chemicals & Botanical Products.

Income

USANA HEALTH SCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Revenue$223.27M$250.22M$226.20M$213.67M$235.85M$249.54M$213.61M$200.22M$212.87M$227.80M
Cost of revenue$48.34M$59.44M$49.41M$48.82M$50.18M$52.44M$38.55M$39.26M$40.33M$43.07M
Gross profit$174.93M$190.78M$176.79M$164.86M$185.66M$197.09M$175.06M$160.96M$172.54M$184.73M
Operating income-$20.00M$13.87M$3.82M$1.22M$16.72M$15.67M$8.21M$15.60M$17.84M$24.67M
Net income-$21.38M$7.52M-$1.78M-$6.52M$9.66M$9.40M$4.45M$10.61M$10.43M$16.54M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 18.49Mshares 18.41MUnavailableshares 18.29Mshares 18.54Mshares 19.08MUnavailableshares 19.08Mshares 19.16Mshares 19.30M
Pretax income-$18.90M$15.46M$4.18M$1.79M$18.82M$16.74M$10.43M$18.61M$20.20M$27.11M
Income tax expense$9.05M$8.51M$5.77M$8.46M$8.37M$7.45M$5.94M$8.00M$9.77M$10.57M
Diluted EPS$-1.16$0.41Unavailable$-0.36$0.52$0.49Unavailable$0.56$0.54$0.86
Selling, general & administrative$82.32M$88.25M$78.08M$85.95M$81.91M$91.44M$73.35M$61.30M$64.32M$64.30M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

USANA HEALTH SCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Cash & equivalents$168.56M$162.75M$158.38M$145.35M$151.34M$179.61M$181.77M$364.89M$332.42M$328.34M
Total assets$703.21M$738.97M$742.92M$726.59M$734.53M$746.60M$748.19M$671.31M$631.42M$629.28M
Current assets$281.07M$294.23M$288.40M$264.06M$261.87M$281.39M$279.19M$451.19M$419.08M$421.07M
Total liabilities$132.24M$144.18M$156.64M$145.04M$148.97M$162.72M$161.86MUnavailableUnavailableUnavailable
Current liabilities$105.68M$117.24M$128.56M$118.66M$121.62M$137.38M$139.62M$114.78M$103.90M$112.63M
Total equity incl. NCI$526.31M$543.55M$533.10M$528.07M$531.06M$529.76M$532.11M$533.09M$512.21M$499.99M
Temporary (mezzanine) equity$44.67M$51.24M$53.17M$53.48M$54.50M$54.11M$54.22MUnavailableUnavailableUnavailable
Inventory$86.34M$96.36M$102.61M$90.78M$83.27M$73.56M$69.74M$63.98M$61.83M$60.87M
Accounts receivable$3.34M$9.66M$4.28MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$109.14M$138.13M$137.96M$144.29M$144.23M$144.22M$144.17M$17.20M$16.84M$16.90M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$15.43M$16.23M$17.26M$16.22M$17.90M$13.97M$11.98M$7.04M$6.65M$8.27M

Cash flow

USANA HEALTH SCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Operating cash flow$23.32M$9.76M-$3.39M-$1.96M$12.22M$15.48M$5.78M$29.53M$7.99M$17.68M
Capital expenditures$3.16M$2.64M$2.80M$3.20M$5.03M$2.80M$1.80M$2.40M$2.67M$3.20M
Investing cash flow-$4.06M-$2.60M$1.11M-$3.20M-$4.16M-$3.88M-$205.14M-$2.34M-$1.55M-$4.07M
Financing cash flow-$14.03M-$3.64M$13.45M-$979.00K-$38.61M-$14.47M$22.93M-$78.00K-$1.35M-$11.95M
Net change in cash$5.85M$4.42M$13.09M-$5.97M-$28.24M-$2.14M-$183.23M$32.57M$4.07M-$2.14M
Stock-based compensation$3.40M$3.45M$3.75M$3.58M$3.62M$2.88M$3.61M$3.54M$3.73M$3.67M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$0$0$0$15.21M$12.30M$0$0$0$9.44M
Depreciation & amortization$7.67M$8.28M$8.56M$7.92M$7.74M$8.34M$4.00M$3.57M$3.81M$3.16M

Derived

USANA HEALTH SCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Free cash flow$20.16M$7.11M-$6.18M-$5.16M$7.19M$12.68M$3.98M$27.14M$5.32M$14.48M
Gross margin78.3%76.2%78.2%77.2%78.7%79.0%82.0%80.4%81.1%81.1%
Operating margin-9.0%5.5%1.7%0.6%7.1%6.3%3.8%7.8%8.4%10.8%
FCF margin9.0%2.8%-2.7%-2.4%3.0%5.1%1.9%13.6%2.5%6.4%
SBC / revenue1.5%1.4%1.7%1.7%1.5%1.2%1.7%1.8%1.8%1.6%
Current ratio2.66x2.51x2.24x2.23x2.15x2.05x2.00x3.93x4.03x3.74x
Revenue YoY growth-5.3%0.3%5.9%6.7%10.8%9.5%-3.4%-6.2%-10.6%-8.3%
Net margin-9.6%3.0%-0.8%-3.1%4.1%3.8%2.1%5.3%4.9%7.3%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue1.4%1.1%1.2%1.5%2.1%1.1%0.8%1.2%1.3%1.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable55.0%138.2%471.3%44.5%44.5%57.0%43.0%48.4%39.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open USNA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.